The data shown in Figure 4 also demonstrate that several drugs and combinations we identified with K562 cell line are effective against BCR-ABL- ALL cells although the selectivity was not as high as for BCR-ABL+ ALL cells or cell lines. This evidence concerns the gene BCR and acute lymphoblastic leukemia.